In the latest trading session, Astrazeneca (AZN) closed at $75.57, marking a +1.79% move from the previous day.

This approval allows the use of Durvalumab in combination with Tremelimumab, broadening treatment options for patients ...

AstraZeneca boasts a remarkably healthy drug portfolio and a pipeline of promising drugs in clinical development. Read why ...

The pharma giant has received the CDSCO nod to import sodium zirconium cyclosilicate powder for oral suspension (Lokelma) in ...

and 109,781 shares under the AstraZeneca Performance Share Plan (AZPSP), both at a price of £119.63 per share. Similarly, Executive Director and CFO Aradhana Sarin received 6,243 shares under the ...

AstraZeneca PLC (NASDAQ:AZN – Get Free Report) has been given an average recommendation of “Buy” by the ten ratings firms that are currently covering the company, Marketbeat.com reports. One equities ...

In the closing of the recent trading day, Astrazeneca (AZN) stood at $77.47, denoting a -0.63% change from the preceding trading day.

AstraZeneca’s share price has dropped recently on concerns relating to its Chinese operation, but this may have left the shares very undervalued. When investing, your capital is at risk.

With this approval, durvalumab can now be used for treating patients with limited-stage small cell lung cancer (LS-SCLC) ...

Retail investors have reduced their stakes in 63 small and midcap stocks, which saw declines between 61% and 20% in 2025. The ...

In the closing of the recent trading day, Astrazeneca (AZN) stood at $76.21, denoting a +0.74% change from the preceding trading day.

AstraZeneca’s (LSE: AZN) share price remains significantly down from its 3 September 12-month traded high of £133.38. Such a drop could signal that the pharmaceuticals giant is fundamentally worth ...